Evidence map›Paper›PMID 39335186›Full record

ArticleCancers2024

Are Dual-Phase

Axel Cailleteau, Ludovic Ferrer, Delphine Geffroy, Vincent Fleury, Paul Lalire, Mélanie Doré, Caroline Rousseau

Abstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Axel CailleteauDepartment of Radiotherapy, ICO René Gauducheau, 44800 Saint Herblain, France.ORCID 0000-0003-3261-6347
Ludovic FerrerDepartment of Nuclear Medicine, ICO René Gauducheau, 44800 Saint Herblain, France.
Delphine GeffroyDepartment of Radiology, ICO René Gauducheau, 44800 Saint Herblain, France.
Vincent FleuryDepartment of Nuclear Medicine, ICO René Gauducheau, 44800 Saint Herblain, France.
Paul LalireDepartment of Nuclear Medicine, ICO René Gauducheau, 44800 Saint Herblain, France.
Mélanie DoréDepartment of Radiotherapy, ICO René Gauducheau, 44800 Saint Herblain, France.
Caroline RousseauDepartment of Nuclear Medicine, ICO René Gauducheau, 44800 Saint Herblain, France.ORCID 0000-0002-0455-0523

Funding

French National Agency for Research "Investissements d'avenir" Labex IRON and Equipex Arronax Plus ANR-11-LABX-0018-01 ANR-11-EQPX-0004
6 · The paper itself

Abstract

Brain metastases or primary brain tumours had poor prognosis until the use of high dose radiotherapy. However, radionecrosis is a complex challenge in the post-radiotherapy management of these patients due to the difficulty of distinguishing this complication from local tumour recurrence. MRI alone has a variable specificity and sensibility, as does PET-CT imaging. We aimed to investigate the diagnostic performance of dual-phase

Indexed as

brain radionecrosiscerebral tumour recurrencecranial radiotherapydual-phase FDGPET-MRI

Identifiers

PMID39335186
PMCPMC11429908

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.